EFFICACY AND SAFETY OF INHALED NITRIC OXIDE USE IN PATIENTS WITH PULMONARY HYPERTENSION AND CHRONIC HEART FAILURE III-IV FUNCTIONAL CLASS, SURVIVED LEFT VENTRICULAR MYOCARDIAL INFARCTION: RESULTS OF NON-RANDOMIZED COMAPARIVE STUDY
https://doi.org/10.17650/1818-8338-2011-3-36-42
Abstract
Aim – assessment of the influence of inhaled nitric oxide (NO) on the course of pulmonary hypertension (PH) in patients with chronic heart
failure (CHF) III–IV functional class (FC), myocardial infarction (MI).
Materials and methods. Results of comparative non-randomized study that included 45 patients (26 men and 19 women aged 51 to 98 years) with PH III–IV functional class, left ventricular myocardial infarction. In the study, patients underwent physical examination and Doppler echocardiography, and assessed FC LH (carried out with six-minute walking test, to determine the degree of dyspnea by Borg).
Results. Symptoms of CHF and PH regressed in both groups of patients against the background of the therapy.
Conclusion. It is established that the use of inhaled NO is a safe therapy and helps to reduce mean pulmonary arterial pressure (PAPmean) in patients with PH and CHF III–IV FC, myocardial infarction. The method of inhaled NO is simple and easy to use.
About the Authors
P. N. Pavlenko
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
O. M. Drapkina
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
I. E. Sergeev
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
V. T. Ivashkin
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
References
1. Ивашкин В.Т., Драпкина О.М. Клиническое значение оксида азота и белков теплового шока. 2-е издание. М.: гэотар-Медиа, 2011.
2. Ивашкин В.Т., Драпкина О.М. Оксид азота в регуляции функциональной активности физиологических систем. Российский журнал гастроэнтерологии, гепатологии, колонопроктологии
3. ;4(3):16–21.
4. Шумаков В.И., Козлов И.А., Попцов В.Н. Ингаляционная окись азота в сердечной и сосудистой хирургии. М., 2000.
5. Kim G. Pulmonary hypertension in infants with bronchopulmonary dysplasia. Korean J Pediatr 2010;53(6):688–93.
6. Ardehali A., Hughes K., Sadeghi A., et al. Inhaled nitric oxide for pulmonary hypertension after heart transplantation. Transplantation 2001;72:638–41.
7. Busch T., Bercker S., Laudi S., et al. Inhaled nitric oxide for rescue treatment of refractory hypoxemia in ARDS patients. Anasthesiol Intensivmed Notfallmed Schmerzther 2008;43(11–12):778–83.
8. Kinsella J., Cutter G., Walsh W., et al. Early inhaled nitric oxide therapy in premature newborns with respiratory failure. N Engl J Med 2006;355:354–64.
9. Creagh-Brown B.C., Griffiths M.J., Evans T.W. Bench-to-bedside review: Inhaled nitric oxide therapy in adults. Crit Care 2009;13(3):221.
10. Paradise W., Vesper B., Goel A., et al. Nitric oxide: perspectives and emerging studies of a well known cytotoxin. Int J Mol Sci 2010;11(7):2715–45.
11. Inglessis I., Shin J., Lepore J., et al. Hemodynamic effects of inhaled nitric oxide in right ventricular myocardial infarction and cardiogenic shock. J Am Coll Cardiol 2004;44:793–8.
12. Hemnes A., Champion H. Right heart function and haemodynamics in pulmonary hypertension. Int J Clin Pract Suppl 2008;(160):11–9.
13. O’Callaghan D., McNeil K. Pulmonary hypertension and left heart disease: emerging concepts and treatment strategies. Int J Clin Pract Suppl 2008;(160):29–31.
14. Galie N., Hoeper M., Humbert M., et al.; ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the
15. European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30(20):2493–537.
16. Guyton A.C., Hall J.E. Textbook of medical physiology. 10th ed. Saunders Elsevier, 2000.
17. Chemla D., Castelain V., Hervé P., et al. Haemodynamic evaluation of pulmonary hypertension. Eur Respir J 2002;20:1314–31.
18. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111–7.
19. Galie N., Seeger W., Naeije R., et al. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(12 Suppl S):81–8.
20. Gomberg-Maitland M., Gaine S. The evolving epidemiology of pulmonary arterial hypertension. Int J Clin Pract Suppl 2009;(161):1–3.
Review
For citations:
Pavlenko P.N., Drapkina O.M., Sergeev I.E., Ivashkin V.T. EFFICACY AND SAFETY OF INHALED NITRIC OXIDE USE IN PATIENTS WITH PULMONARY HYPERTENSION AND CHRONIC HEART FAILURE III-IV FUNCTIONAL CLASS, SURVIVED LEFT VENTRICULAR MYOCARDIAL INFARCTION: RESULTS OF NON-RANDOMIZED COMAPARIVE STUDY. The Clinician. 2011;5(3):36-42. (In Russ.) https://doi.org/10.17650/1818-8338-2011-3-36-42
Views:
1226
Email this article 